Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel

On Wednesday, Hims & Hers Health, Inc. HIMS launched the Service Appreciation Initiative, offering compounded GLP-1 weight loss medications to some personnel for as low as $99 per month.

The initiative covers eligible U.S. military personnel, veterans, teachers, nurses, and first responders.

Hims & Hers Health is a telehealth company known for offering compounded alternatives to popular GLP-1 weight-loss treatments. Its shares have soared over 120% since August 2023.

Also Read: Battle Over Compounded Weight-Loss Medications – Sustainability and Regulation

The platform has already seen success, with over 12,000 customers reporting significant weight loss—an average of 10.2 pounds with compounded GLP-1 injections and 6.3 pounds with non-GLP-1 oral medications—within four weeks of starting treatment.

The issue of obesity is particularly significant in service roles. Studies have shown that around 70% of American adults are overweight or obese, and the rates are alarmingly high among veterans, military personnel, teachers, nurses, police officers, and firefighters.

Stress, sleep disruption, and other occupational hazards contribute to these statistics, making the need for affordable weight loss solutions even more urgent.

Novo Nordisk A/S NVO CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company's blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.

Earlier this year, a study revealed that Ozempic could be produced for less than $5 a month, starkly contrasting its current monthly price of $968.52. Similarly, Wegovy is priced at $1,349.02 per month.

Senator Bernie Sanders, chair of the Health, Education, Labor and Pensions (HELP) Committee, has been vocal about the stark price differences for Ozempic and Wegovy between the U.S. and other countries.

Novo Nordisk CEO Lars Jorgensen is scheduled to appear before the Senate HELP Committee, led by Chairman Bernie Sanders, for a hearing next week that will focus on hearing popular drugs, Ozempic, and Wegovy in the U.S.

Price Action: HIMS stock is up 3.49% at $16.88 at last check Thursday.

Read Next:

• Amazon Boosts Worker Pay to Over $29/Hour, Invests $2.2B As Holiday Kicks In.

Photo via Shutterstock